Sanofi CEO Paul Hudson on AI and Innovation as the Pharmaceutical Industry’s Only Defense

During a live discussion at Davos, Sanofi CEO Paul Hudson joined CNBC’s Squawk Box to offer commentary on the pharmaceutical landscape, including the political pressures surrounding drug pricing, the imperative for global health equity, and the transformative role of Artificial Intelligence (AI) in research and development. Hudson’s core message was clear: in an era of intense political scrutiny and mounting global health challenges, relentless innovation, particularly through AI adoption, is the only viable strategy for pharmaceutical companies to maintain relevance and resilience.

The conversation began by addressing the political climate, particularly in the U.S. and Europe, where drug pricing remains a contentious issue. Hudson expressed encouragement regarding the energy being directed toward addressing health inequity, suggesting that this focus ultimately "bodes well for access to innovation." However, he acknowledged the underlying pressure from governments, including the U.S. administration, which is pushing for other developed countries to pay higher prices for medications to balance out costs. This pressure, as one interviewer noted, represents a significant threat to the traditional pharmaceutical business model. Hudson’s response was measured yet firm, asserting that “Innovation is the only thing we know will be rewarded.” For Sanofi, navigating this complexity means aggressively pursuing breakthroughs—specifically focusing on rare diseases and unmet needs—which health systems will inherently be willing to pay for because they “get people back to work, they change, save or protect lives.”

Sanofi’s long-term strategy, as articulated by Hudson, is fundamentally predicated on achieving double-digit growth, a plan that requires an aggressive pivot toward groundbreaking research. This shift is being fueled by a deep integration of AI across the company’s R&D governance and decision-making processes. Hudson highlighted that the company has “completely reinvented how we do R&D,” recognizing that while the pace of biological discovery remains fixed, the process of drug development can be dramatically accelerated. AI is not just a tool for optimization; it’s a mechanism for injecting objectivity into high-stakes decisions.

The CEO offered a sharp insight into how AI is changing the internal dynamic of drug development. He explained that in crucial decision-making meetings, they now utilize AI as a "neutral voice in the room," asking the system for its objective recommendation before the human team begins its debate. This approach, Hudson contends, allows the company to be "radically objective" and introduce a necessary level of dispassion that offsets the human tendency toward career-driven bias in long-term projects. This implementation of AI governance represents a significant cultural and operational evolution, designed to “strip a lot out of the timeline” and ultimately accelerate the pace of bringing novel, first-in-class therapies to market.

This urgency for efficiency and innovation is paramount, especially given the difficulty and high cost associated with researching rare diseases—a key focus area for Sanofi. Hudson acknowledged that while treating small patient populations presents inherent profitability challenges, Sanofi is committed to this work, noting, “We have a duty to do that work. That’s why most of us are in healthcare.” The ability to run a successful business while simultaneously pursuing these complex, high-impact areas is directly tied to the company’s ability to streamline its operations and accelerate its pipeline through technology. Sanofi positions itself as one of the “earliest adopters broadly in AI in pharma,” expecting that this early commitment will yield significant results over the next 12 to 24 months, fundamentally changing both the cost and speed of drug development. The successful commercial performance Sanofi has recently delivered provides the necessary financial runway, but the long-term protection against political and market volatility remains innovation itself.

Hudson’s commentary served as a powerful declaration that the future of the pharmaceutical industry belongs to those who embrace radical innovation and operational efficiency, driven by AI. In a landscape where profitability is constantly challenged by political demands for lower prices and greater equity, the only sustainable defense is to produce medicines so revolutionary that their value proposition is undeniable to patients, governments, and investors alike.